Welcome to our dedicated page for Structure Therapeutics ADR SEC filings (Ticker: GPCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Structure Therapeutics Inc. SEC filings document a Cayman Islands clinical-stage biopharmaceutical issuer whose Nasdaq-listed American depositary shares each represent three ordinary shares. The filings identify the company’s ADS and ordinary-share structure, Exchange Act reporting status, material agreements, and formal corporate-governance matters.
Recent 8-K reports cover financial results and corporate updates, Regulation FD disclosures for aleniglipron clinical data, amendments to a sales agreement, executive appointment and compensation matters, and shareholder-vote results. Proxy materials describe annual general meeting proposals, director elections, auditor ratification, advisory executive-compensation votes, board governance, and related shareholder procedures.
Structure Therapeutics Inc. furnished a current report describing a new press release that provides a corporate update and the company’s financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference for those detailed results.
The report clarifies that this information, including Exhibit 99.1, is furnished rather than filed under securities laws, which affects how it is treated for liability and incorporation into other regulatory documents.
Structure Therapeutics insider transaction: Reporting person Ashley Hall, identified as Chief Development Officer and a director, had 6,021 ordinary shares withheld to satisfy income tax obligations related to the vesting of restricted share units on 09/18/2025. The shares were recorded at a price of $7.7433 per share and reduced Hall's beneficial ownership to 112,317 ordinary shares. The filing notes that the issuer's ordinary shares may be represented by ADSs, with each ADS equal to three ordinary shares. This appears to be a routine tax-withholding disposition following equity vesting rather than an open-market sale.
Structure Therapeutics insider transaction: Reporting person Ashley Hall, identified as Chief Development Officer and a director, had 6,021 ordinary shares withheld to satisfy income tax obligations related to the vesting of restricted share units on 09/18/2025. The shares were recorded at a price of $7.7433 per share and reduced Hall's beneficial ownership to 112,317 ordinary shares. The filing notes that the issuer's ordinary shares may be represented by ADSs, with each ADS equal to three ordinary shares. This appears to be a routine tax-withholding disposition following equity vesting rather than an open-market sale.
Coll Crespo Blas, Chief Medical Officer of Structure Therapeutics Inc. (GPCR), reported a change in beneficial ownership for ordinary shares on 09/18/2025. The filing shows 8,106 ordinary shares were disposed (D) at a reported price of $7.7433 per share. After the transaction the reporting person beneficially owned 216,807 ordinary shares. The filing explains the 8,106 shares represent shares withheld by the issuer to satisfy income tax obligations related to the vesting of a restricted share unit award. The form notes that the issuer’s ordinary shares may be represented by ADSs, with each ADS equal to three ordinary shares.
Coll Crespo Blas, Chief Medical Officer of Structure Therapeutics Inc. (GPCR), reported a change in beneficial ownership for ordinary shares on 09/18/2025. The filing shows 8,106 ordinary shares were disposed (D) at a reported price of $7.7433 per share. After the transaction the reporting person beneficially owned 216,807 ordinary shares. The filing explains the 8,106 shares represent shares withheld by the issuer to satisfy income tax obligations related to the vesting of a restricted share unit award. The form notes that the issuer’s ordinary shares may be represented by ADSs, with each ADS equal to three ordinary shares.
Ma Yingli, Chief Technology Officer and director of Structure Therapeutics Inc. (GPCR), reported a Form 4 showing a transaction on 07/01/2025. The filing discloses a disposition of 4,470 ordinary shares at a price of $6.8366 per share, leaving 118,704 ordinary shares beneficially owned following the transaction.
The Form 4 notes these shares were withheld by the issuer to satisfy income tax obligations related to the vesting of a restricted share unit award. The report was executed by an attorney-in-fact, Jun Yoon, and is part of routine insider reporting under Section 16.
Structure Therapeutics Inc. (GPCR) reporting person Lin Xichen, who serves as Chief Scientific Officer and a director, disclosed a transaction on 07/01/2025 affecting her beneficial ownership. The filing shows 12,846 ordinary shares were disposed of through withholding to satisfy income tax obligations tied to the vesting of a restricted share unit award; the per‑share price reported for that disposition was $6.8366.
After the withholding transaction, Lin Xichen beneficially owns 204,327 ordinary shares, held directly. The filing notes that the company’s ordinary shares may be represented by ADSs, with each ADS equal to three ordinary shares. The form is a routine Section 16 report itemizing an insider tax‑related share withholding.
Structure Therapeutics Inc. received a Schedule 13G disclosing positions held by a group of affiliated Biotechnology Value Fund entities and Mark N. Lampert. Collectively the Reporting Persons beneficially own 9,611,751 Ordinary Shares, representing approximately 5.6% of the 172,793,818 shares outstanding (including ADSs) based on the issuer's July 31, 2025 share count. Individual holdings include BVF with 4,986,351 shares (about 2.9%), BVF2 with 3,902,022 shares (about 2.3%) and a Trading Fund OS with 530,763 shares (about 0.3%). The filing states these holdings were not acquired to change or influence control of the issuer.
Janus Henderson Group plc filed Amendment No. 3 to a Schedule 13G reporting ownership in Structure Therapeutics Inc. The filing lists 4,573,006 American Depositary Shares, representing 8.0% of the class, with shared voting and dispositive power. A subsidiary disclosure shows JHIUS may be deemed beneficial owner of 4,449,167 shares (7.7%) with shared voting and dispositive power. The report cites the event date 06/30/2025 and is signed on 08/14/2025 by Kristin Mariani. The filer certifies the position is held in the ordinary course and not to influence control. A power of attorney executed on 12/09/2022 is attached.
Structure Therapeutics Inc. Schedule 13G discloses that Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin jointly report beneficial ownership of 15,401,751 ordinary shares, representing 8.92% of the class based on 172,610,249 shares outstanding. The position is held through 5,133,917 American Depositary Shares, each convertible into three ordinary shares.
The filing states the reporting persons have shared voting and dispositive power over the shares and no sole voting or dispositive power, includes a joint filing statement on amendment responsibilities, and certifies the stake is not held to change or influence control.
Wellington Management disclosed beneficial ownership of 20,627,307 shares of Structure Therapeutics common stock, representing 11.95% of the class. The filing shows no sole voting or dispositive power and reports shared voting power of 19,646,661 and shared dispositive power of 20,627,307, indicating these securities are managed jointly across Wellington entities. The shares are owned of record by clients of Wellington Investment Advisers rather than by Wellington as principal.
The filing also states the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. One named client, Vanguard Health Care Fund, is identified as an exception to the general statement about clients.